Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Clinical Management of Neuropathic Pain With Ramelteon

This study has been terminated.
(Recruitment did not accrue as expected.)
Sponsor:
Collaborator:
Takeda Pharmaceuticals North America, Inc.
Information provided by (Responsible Party):
Jianren Mao, MD, PhD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00753623
First received: September 15, 2008
Last updated: April 3, 2017
Last verified: April 2017
Results First Received: November 1, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: Participant, Care Provider, Investigator;   Primary Purpose: Treatment
Condition: Neuropathic Pain
Interventions: Drug: Ramelteon
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were recruited in person at the MGH Center for Pain or by advertisement throughout MGH and the local community.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Placebo Phase I; Ramelteon Phase II

In a crossover design, a subject was first assigned to the placebo and then switched over to the ramelteon.

Ramelteon : ramelteon (8 mg)

Ramelton Phase I; Placebo Phase II

In a crossover design, a subject was first assigned to the ramelteon and then switched over to the placebo.

Ramelteon : ramelteon (8 mg)


Participant Flow for 3 periods

Period 1:   Phase I (14 Days)
    Placebo Phase I; Ramelteon Phase II   Ramelton Phase I; Placebo Phase II
STARTED   11   12 
COMPLETED   9   8 
NOT COMPLETED   2   4 
Withdrawal by Subject                1                1 
Physician Decision                1                2 
Adverse Event                0                1 

Period 2:   Washout (7 Days)
    Placebo Phase I; Ramelteon Phase II   Ramelton Phase I; Placebo Phase II
STARTED   9   8 
COMPLETED   8   8 
NOT COMPLETED   1   0 
Physician Decision                1                0 

Period 3:   Phase II (14 Days)
    Placebo Phase I; Ramelteon Phase II   Ramelton Phase I; Placebo Phase II
STARTED   8   8 
COMPLETED   8   7 
NOT COMPLETED   0   1 
Physician Decision                0                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo Phase I; Ramelteon Phase II

In a crossover design, a subject was first assigned to the placebo and then switched over to the ramelteon.

Ramelteon : ramelteon (8 mg)

Ramelton Phase I; Placebo Phase II

In a crossover design, a subject was first assigned to the ramelteon and then switched over to the placebo.

Ramelteon : ramelteon (8 mg)

Total Total of all reporting groups

Baseline Measures
   Placebo Phase I; Ramelteon Phase II   Ramelton Phase I; Placebo Phase II   Total 
Overall Participants Analyzed 
[Units: Participants]
 11   12   23 
Age 
[Units: Participants]
Count of Participants
     
<=18 years      0   0.0%      0   0.0%      0   0.0% 
Between 18 and 65 years      11 100.0%      12 100.0%      23 100.0% 
>=65 years      0   0.0%      0   0.0%      0   0.0% 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      7  63.6%      5  41.7%      12  52.2% 
Male      4  36.4%      7  58.3%      11  47.8% 
Region of Enrollment 
[Units: Participants]
Count of Participants
     
United States   11   12   23 


  Outcome Measures

1.  Primary:   Difference in Visual Analog Scale (VAS) for Pain (0-10) Between Treatments   [ Time Frame: VAS score at baseline and after the treatment period ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Problems with recruitment and termination of the study consequently resulted in uninterpretable data.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Jianren Mao
Organization: MGH Center for Translational Pain Research
phone: 617-724-6102
e-mail: mghpainresearch@partners.org



Responsible Party: Jianren Mao, MD, PhD, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00753623     History of Changes
Other Study ID Numbers: 2008P-000988
Study First Received: September 15, 2008
Results First Received: November 1, 2013
Last Updated: April 3, 2017